May 23, 2013

Nasdaq

Portola Pharmaceuticals prices upsized IPO at $14.50, within the range

Portola Pharmaceuticals, which is developing a blood thinner and a novel reversal agent for acutely ill patients, raised $122 million in an upsized IPO by offering 8.4 million shares at $14.50, the midpoint of the $13 to $16 range. Portola commands a market cap of $491 million. The company originally set terms for a deal that would have raised $100 million at the midpoint and valued the company at a market cap of $469 million. 

Read more: http://www.nasdaq.com/article/portola-pharmaceuticals-prices-upsized-ipo-at-1450-within-the-range-cm247831#ixzz2UgziVCrJ